Product Description
MT-4129 is a highly selective and potent aldosterone synthase inhibitor that is being investigated for the treatment of hypertension
Mechanisms of Action: Aldosterone Synthase Inhibitor
Novel Mechanism: Yes
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Mitsubishi Tanabe
Company Location: Asia Pacific
Company Founding Year: 2007
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02953132 |
MT-4129-E01 | P1 |
Completed |
Healthy Volunteers |
2017-05-01 |
2023-04-08 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|